$PTHS News

Oppenheimer Maintains Outperform on Pelthos Therapeutics, Lowers Price Target to $64

Pelthos Therapeutics Inc. (PTHS) Q2 2026 Earnings Call Transcript

Pelthos Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript

Pelthos Therapeutics Q2 EPS $(6.62) Misses $(3.05) Estimate, Sales $15.603M Beat $15.273M Estimate

Pelthos Therapeutics Joins The Russell 3000E Growth Benchmark, Russell Microcap And Russell Microcap Growth Benchmark Indexes

Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $66

Pelthos Therapeutics Inc. (PTHS) Q1 2026 Earnings Call Transcript

Pelthos Therapeutics Inc (NYSEARCA:PTHS) Revenue Beats Estimates in Q1 2026, Net Loss Narrows

Pelthos Therapeutics Q1 2026 Earnings Call Transcript

Pelthos Therapeutics Q1 EPS $(3.09) Beats $(3.81) Estimate, Sales $10.906M Beat $10.445M Estimate

Pelthos Therapeutics Appoints John M. Gay As CFO

Pelthos Therapeutics Announces First Patient Dosed In Phase 1b/2a Clinical Trial Evaluating CT2000 As Potential Treatment For Eye Pain

Pelthos Therapeutics Maps Public-Market Path, ZELSUVMI Surge, Adds Xepi and Xeglyze in Roth Interview

Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $62

Pelthos Therapeutics Inc (PTHS) Q4 2025 Earnings Call Highlights: Prescription Surge and ...

Pelthos Therapeutics Q4 Earnings Call Highlights

Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript

HC Wainwright & Co. Reiterates Buy on Pelthos Therapeutics, Maintains $60 Price Target

Pelthos Therapeutics Inc. (PTHS) Reports Strong Q4 2025 Earnings Beat Amid Muted Market Reaction

Pelthos Therapeutics Inc. (PTHS) Reports Q4 Loss, Tops Revenue Estimates